OMER, Israel, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Medigus Ltd. (NASDAQ: MDGS) (TASE: MDGS), a medical device
company developing minimally invasive endo-surgical tools and an innovator in direct visualization technology, announced today that
it is considering expanding its portfolio of activities to include ventures in the field of cannabidiol (CBD) and medical cannabis
in territories outside the United States.
Further to the company’s previous reports, the company’s management and board of directors continue to decrease
inefficiencies, expand the company’s revenue streams and pursue diversification of its activity portfolio. Keeping with this
strategy, the company announced that it is in the process of learning the CBD and medical cannabis industries and is preliminarily
investigating potential collaborations and activities in this space, outside of the United States, which could add value to the
company and its shareholders.
About Medigus
Medigus is a medical device company specializing in developing minimally invasive endosurgical tools and highly innovative imaging
solutions. Medigus is the pioneer developer of the MUSE™ system, an FDA cleared and CE marked endoscopic device to perform
Transoral Fundoplication (TF) for the treatment of GERD (gastroesophageal reflux disease), one of the most common chronic
conditions in the world. In 2016, the CMS established the Category I CPT® Code of 43210 for TF procedures, such as the ones
performed with MUSE, which establishes reimbursement values for physicians and hospitals. Medigus is also in the process of
obtaining regulatory clearance in China.
As an expert in micro-endoscopic devices, Medigus developed the Micro ScoutCam™ portfolio, which consists of a
variety of micro CMOS and CCD video cameras, and includes Micro ScoutCam™ 1.2, which, to the best of the company's knowledge, is
the smallest camera in the world. Micro ScoutCam technology features optic and illumination solutions, micro sensors and high-end
DSP video processors that can be tailored for both medical and industrial applications. Customization and seamless integration is
at the forefront of the micro ScoutCam™ portfolio’s design. All Micro ScoutCam™ cameras are manufactured at the Medigus facilities,
in a controlled environment which is compliant with ISO 7 per the ISO 14644-1 Standard and ISO13485 Quality Management System.
Medigus is traded on the Nasdaq Capital Market and the TASE (Tel Aviv Stock Exchange). To learn more about the
company’s advanced technology, please visit www.medigus.com or www.RefluxHelp.com
This press release may contain statements that are “Forward-Looking Statements,” which are based upon the
current estimates, assumptions and expectations of the company’s management and its knowledge of the relevant market. The company
has tried, where possible, to identify such information and statements by using words such as “anticipate,” “believe,” “envision,”
“estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,”
“continue,” “contemplate” and other similar expressions and derivations thereof in connection with any discussion of future events,
trends or prospects or future operating or financial performance, although not all forward-looking statements contain these
identifying words. These forward-looking statements represent Medigus’ expectations or beliefs concerning future events, and it is
possible that the results described in this press release will not be achieved. By their nature, Forward-Looking Statements involve
known and unknown risks, uncertainties and other factors which may cause future results of the company’s activity to differ
significantly from the content and implications of such statements. Other risk factors affecting the company are discussed in
detail in the company's filings with the Securities and Exchange Commission. Forward-Looking Statements are pertinent only as of
the date on which they are made, and the company undertakes no obligation to update or revise any Forward-Looking Statements,
whether as a result of new information, future developments or otherwise. Neither the company nor its shareholders, officers and
employees, shall be liable for any action and the results of any action taken by any person based on the information contained
herein, including without limitation the purchase or sale of company securities. Nothing in this press release should be deemed to
be medical or other advice of any kind.
Contact (for media only):
Oded Yatzkan
Chief Financial Officer
+972-8-6466-880
ir@medigus.com
